TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes

New England Journal of Medicine

Volumn 375, Issue 21, 2016, Pages 2023-2036

  Welch, J S ^a   Petti, A A ^a   Miller, C A ^a   Fronick, C C ^a   O'Laughlin, M ^a   Fulton, R S ^a   Wilson, R K ^a   Baty, J D ^a   Duncavage, E J ^a   Tandon, B ^a   Lee, Y S ^a   Wartman, L D ^a   Uy, G L ^a   Ghobadi, A ^a   Tomasson, M H ^a   Pusic, I ^a   Romee, R ^a   Fehniger, T A ^a   Stockerl Goldstein, K E ^a   Vij, R ^a   Oh, S T ^a   Abboud, C N ^a   Cashen, A F ^a   Schroeder, M A ^a   Jacoby, M A ^a   Heath, S E ^a   Luber, K ^a   Janke, M R ^a   Hantel, A ^b   Khan, N ^b   Sukhanova, M J ^b   Knoebel, R W ^b   Stock, W ^b   Graubert, T A ^c   Walter, M J ^a   Westervelt, P ^a   Link, D C ^a   Dipersio, J F ^a   Ley, Timothy J ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; PROTEIN P53; 5 METHYLCYTOSINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BODY SURFACE; BONE MARROW; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SOMATIC MUTATION; TREATMENT RESPONSE; WILD TYPE; AGED; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; EXOME; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MUTATION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

5-METHYLCYTOSINE; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOMARKERS, TUMOR; BONE MARROW; EXOME; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84996615311     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1605949     Document Type: Article

References (36)

1. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015;125:1367-76.
2. Klepin HD. Myelodysplastic syndromes and acute myeloid leukemia in the elderly. Clin Geriatr Med 2016;32:155-73.
3. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012;119:2114-21.
4. Ohgami RS, Ma L, Merker JD, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol 2015;28:706-14.
5. Sallman DA, Komrokji R, Vaupel C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 2016;30:666-73.
6. Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J 2015;5:e331.
7. Malik P, Cashen AF. Decitabine in the treatment of acute myeloid leukemia in elderly patients. Cancer Manag Res 2014;6:53-61.
8. Kim TK, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol 2015;52:172-83.
9. Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma 2013;54:2003-7.
10. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473-8.
11. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605-13.
12. Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 2012;120:2466-74.
13. Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol 2012;91:1879-86.
14. Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012;26:1106-7.
15. DiNardo CD, Patel KP, Garcia-Manero G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma 2014;55:1925-9.
16. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014;124:2705-12.
17. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015;314:811-22.
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
19. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
20. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74.
21. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556-61.
22. Wong TN, Miller CA, Klco JM, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 2016;127:893-7.
23. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477-87.
24. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-98.
25. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012;44:642-50.
26. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014;20:1472-8.
27. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009;115:5746-51.
28. Lübbert M, Suciu S, Hagemeijer A, et al. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Ann Hematol 2016;95:191-9.
29. Lafouresse F, Bellard E, Laurent C, et al. L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo. Blood 2015;126:1336-45.
30. Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 2009;23:203-6.
31. Middeke JM, Herold S, Rücker-Braun E, et al. TP53 mutation in patients with highrisk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol 2016;172:914-22.
32. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
33. Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res 2015;39:520-4.
34. Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 2013;121:1633-43.
35. Roulois D, Loo Yau H, Singhania R, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015;162:961-73.
36. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010;116:129-39.